Table 2 |
||||||
|
Summary of VTE and Major Bleeding Rates in Trials Comparing Extended-Duration Thromboprophylaxis Strategies in Cancer Patients |
||||||
|
Ref. |
Cancer |
Patients, N |
Drug |
VTE Detection |
VTE, % |
Bleeding*, % |
|
|
||||||
|
[48] |
Gastrointestinal, genitourinary, gynecological |
167 |
Enoxaparin 40 mg SC 6--10 days plus placebo 19--21 days |
Symptomatic and asymptomatic VTE: DVT - venography; PE - VPS, pulmonary angiography |
12 |
3.6 (minor) 3.6 (major) |
|
|
|
|||||
|
165 |
Enoxaparin 40 mg SC 25--31 days |
4.8 |
4.7 (minor) 5.1 (major) |
|||
|
|
||||||
|
[49] |
Abdominal (all patients)† |
178 |
Dalteparin 5,000 IU OD plus GCS for 7 days |
Symptomatic and asymptomatic VTE: DVT - venography; PE - VPS, spiral computerized tomography, autopsy |
16.3 |
0.9 (minor) 1.8 (major) |
|
|
|
|||||
|
165 |
Dalteparin 5,000 IU SC OD plus GCS for 7 days, plus further 21 days |
7.3 |
1.5 (minor) 0.5 (major) |
|||
|
|
||||||
|
[50] |
Abdominal cancer sub-group |
198 total |
Dalteparin 5,000 IU OD plus GCS for 7 days |
19.6 proximal DVT: 10.4 |
Not reported |
|
|
|
|
|||||
|
Dalteparin 5,000 IU SC OD plus GCS for 7 days, plus further 21 days |
8.8 proximal DVT: 2.2 |
|||||
|
|
||||||
|
DVT, deep vein thrombosis; GCS, graduated compression stockings; OD, once daily; PE, pulmonary embolism; SC, subcutaneous; VPS; ventilation perfusion scan; VTE, venous thromboembolism. * For definitions of major bleeding see original studies. †Included non-cancer patients |
||||||
|
Robert Journal of Hematology & Oncology 2010 3:3 doi:10.1186/1756-8722-3-3 |
||||||
